London, 3 August 2026 — EBM Newsdesk Analysis — By Nick Staunton
AstraZeneca shares fell as much as 7% in London on 3 August, closing in on 11,804p, after the Financial Times reported the company had spent recent months in merger discussions with Bristol Myers Squibb. Bristol Myers rose 2.7% in pre-market trading. A combination would be worth around $400bn and rank fourth among global pharmaceutical groups. Both companies declined to comment, and the FT’s sources cautioned the talks may be delayed or collapse entirely.
The share price reaction is the story. When a market marks the acquirer down 7% and the target up on the same headline, it is not expressing uncertainty about execution. It is saying the buyer is paying, and the seller is being rescued.
Join The European Business Briefing
New subscribers this quarter are entered into a draw to win a Rolex Submariner. Join 40,000+ founders, investors and executives who read EBM every day.
SubscribeWhat Each Side Brings
AstraZeneca carries a market capitalisation of roughly $264bn against Bristol Myers’ $133bn, making this an acquisition in everything but presentation. Pascal Soriot has run AstraZeneca for fourteen years, during which the shares have more than quadrupled and comfortably outpaced the wider FTSE 100. He is the man who rebuffed Pfizer’s $118bn approach in 2014 and was proved emphatically right.
Bristol Myers arrives from a weaker position. It faces patent expiries on key drugs, generic competition, and has been cutting research spending — GAAP R&D fell around 11% to roughly $10bn in 2025. It has been buying pipeline rather than building it.
The awkward part is that AstraZeneca said recently it did not need M&A to hit its targets. Chris Beauchamp at IG noted drily that companies saying one thing and doing another is a well-trodden path.
The British Company That Keeps Moving West
For European readers the interesting question is not whether the deal completes. It is what it says about where AstraZeneca now believes its future lies.
Britain’s second most valuable company completed an additional New York listing in June, has committed $50bn to American manufacturing and research, and is now discussing a merger with a New Jersey pharmaceutical group. Any transaction would be reviewed by an administration that has made onshoring investment an explicit policy goal — which means the regulatory path runs through Washington, not Brussels or London.
Each step has a clean commercial rationale. Taken together they describe a company progressively relocating its centre of gravity while keeping a London listing, the same drift now visible across European capital markets and in Europe’s growth capital.
The Verdict
Soriot has earned considerable benefit of the doubt, and it is possible he sees something in the Bristol Myers pipeline the market has missed. He has been right before against louder opposition.
But the pattern is familiar. Large pharmaceutical mergers are usually a response to a patent cliff, and they usually deliver cost synergies rather than drugs. Investors reached that conclusion before lunch.
For Britain, the more uncomfortable point is structural. Losing a company’s headquarters is a visible event that prompts questions in Parliament. Losing its centre of gravity happens quietly, one sensible decision at a time, and nobody calls a debate about it.
